The ability to provide long-acting reversible contraceptive to adolescents seeking birth control on the same day as their clinic visit is linked with potentially significant cost savings for insurance providers, according to a study.
Providing adolescents seeking birth control with the ability to receive long-acting reversible contraceptive (LARC) on the same day as their clinic visit is linked with potentially significant cost savings for insurance providers, according to a study published this week in the journal JAMA Network Open.
Indiana University School of Medicine study authors Tracey A. Wilkinson, MD, assistant professor of pediatrics; Brownsyne Tucker Edmonds, MD, associate professor of obstetrics and gynecology; and Stephen M. Downs, vice chair of general pediatrics, evaluated Indiana’s potential Medicaid cost savings attributed to providing same-day access of LARC to adolescents.
Cost is an underlying barrier to entry for adolescents seeking LARC. As Wilkinson highlighted in a statement, “I quickly realized there were few clinical sites providing same-day LARC. They are more expensive, but they are very effective, because they don’t require any user dependence in order to work."
While considered the most effective contraception for adolescents, LARC normally requires multiple clinic visits, which contributes to costs and heightened probabilities related to device insertions and removals, unintended pregnancy, and births. Researchers created a cost minimization model to determine the economic cost to Medicaid for variables such as additional visits, the device, and the cost of delivering a baby.
“We thought about the typical young woman seeking contraception and drew a branching tree representing all of the things that might happen if she could or could not get it that day,” said Downs.
Costs were compared based on distinction of same-day LARC and return-visit strategy for LARC placement after subsequent visits. Correlated rates of unintended pregnancy and abortion were additionally determined:
The substantial decrease in costs associated with administering LARC on the same day stresses its potential regardless of its expensive implementation. As 85% of all adolescent pregnancies in the United States are unintended, same-day LARC can significantly cut these probabilities and subsequent costs for Medicaid. Improving health disparities in minority and low-income women and infants of color, who are disproportionately affected by infant prematurity and mortality, was further emphasized by Edmonds.
The researchers provided 4 recommendations to state Medicaid officials to enhance same-day LARC distribution based on their findings:
“When you have people who desire contraception not being able to access it, the outcomes of all our communities are less than ideal. Planned pregnancies are healthier pregnancies are healthier pregnancies, so having same-day access to all forms of contraception is vital,” said Wilkinson.
Reference
Wilkinson TA, Downs SM, Edmonds BT. Cost Minimization Analysis of Same-Day Long-Acting Reversible Contraception for Adolescents. [published online September 11, 2019]. JAMA Network Open. doi: 10.1001/jamanetworkopen.2019.11063.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More